CLINICAL TRIALS PROFILE FOR PALIPERIDONE
✉ Email this page to a colleague
All Clinical Trials for paliperidone
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00073320 ↗ | Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2003-08-01 | The purpose of the study is to compare the pharmacokinetic parameters (blood concentrations) of i.m. paliperidone palmitate after administration in 2 different injection sites (deltoid or gluteal). |
| NCT00074477 ↗ | Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | 2003-10-01 | The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate injection compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings. |
| NCT00077714 ↗ | Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2004-01-01 | The purpose of this trial is to determine if paliperidone ER is an effective treatment for adults with schizophrenia. |
| NCT00078039 ↗ | Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2004-03-01 | The primary objective of the double blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (6, 9, and 12 mg/day) compared with placebo in adult patients with schizophrenia. |
| NCT00083668 ↗ | Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2004-04-01 | The primary objective of the double-blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (3, 9, and 15 mg/day) compared with placebo in adult patients with schizophrenia |
| NCT00085748 ↗ | Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2004-08-01 | The primary objective of the study is to evaluate the safety and tolerability of flexible dosages of paliperidone ER as compared with placebo in patients with schizophrenia who are 65 years of age or older. The primary objective of the open-label extension is the long-term assessment of safety and tolerability of paliperidone ER in patients diagnosed with schizophrenia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for paliperidone
Condition Name
Clinical Trial Locations for paliperidone
Trials by Country
Clinical Trial Progress for paliperidone
Clinical Trial Phase
Clinical Trial Sponsors for paliperidone
Sponsor Name
